6410821A-1C6A-4F64-939F-196313B8F1E5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.914586070959263
- age_years
- 60
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AB5294B5-4A59-493A-9016-C2778735745F | — | — | 0.977 |
| 2 | 93708EED-CBE1-4B2E-A571-34316ACFE748 | — | — | 0.974 |
| 3 | AF548E30-7121-4F9F-A2CD-F1A540E9C4EE | — | — | 0.972 |
| 4 | E89DB941-19C3-4CD9-9117-EAAF3B2AFD76 | — | — | 0.967 |
| 5 | CC9815B3-88D0-4376-B96F-B979E1FBD0C7 | — | — | 0.965 |
| 6 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.965 |
| 7 | E7BE221B-273D-4C04-BE79-366E6455EFBC | — | — | 0.963 |
| 8 | 97A8E2B1-059B-4527-8FB4-116F718FFD16 | — | — | 0.957 |
| 9 | DF145DF3-D7FD-48C9-ADC8-0B8618DC65A8 | — | — | 0.956 |
| 10 | BB96C5BA-CA50-40B4-B22A-3FCFE46AB11C | — | — | 0.955 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.606 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.592 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.559 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.523 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.504 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.477 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.458 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.453 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.434 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.422 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.406 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.396 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.392 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.388 | Idelalisib | — uncovered |
| APOPTOSIS | 0.382 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.373 | Inavolisib | — uncovered |
| COMPLEMENT | 0.357 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.354 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.349 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.316 | Idelalisib | — uncovered |